• Home
  • Practice Focus
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
    • How I Do It
    • TRIO Best Practices
  • Business of Medicine
    • Health Policy
    • Legal Matters
    • Practice Management
    • Tech Talk
    • AI
  • Literature Reviews
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Career
    • Medical Education
    • Professional Development
    • Resident Focus
  • ENT Perspectives
    • ENT Expressions
    • Everyday Ethics
    • From TRIO
    • The Great Debate
    • Letter From the Editor
    • Rx: Wellness
    • The Voice
    • Viewpoint
  • TRIO Resources
    • Triological Society
    • The Laryngoscope
    • Laryngoscope Investigative Otolaryngology
    • TRIO Combined Sections Meetings
    • COSM
    • Related Otolaryngology Events
  • Search

Is It Time to De-Escalate Radiation Therapy in Patients with HPV+ HNC?

by Karen Appold • November 10, 2019

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

Proceed with Caution

As exciting as the concept of de-escalating treatment for patients with HPV+ oropharynx cancers might be, Andrew Sikora, MD, PhD, associate professor and vice chair for research in the department of otolaryngology at Baylor College of Medicine in Houston, said that it’s important to make sure that the desire to improve patients’ quality of life doesn’t lead to worsening excellent survival outcomes. “Any de-escalation strategy needs to be based on a foundation of solid clinical trials evidence,” he added.

You Might Also Like

  • Study: Surgery, Radiation Therapy Equally Effective in Treating OPSCC
  • Primary Radiation vs. Primary Surgical Therapy for Cervical Esophageal Cancer
  • Fanconi Anemia Patients with HNSCC Tolerate Surgery Better than Radiation, Chemotherapy
  • HPV-Positive Oropharnygeal Cancer Has Better Prognosis than Tobacco-Induced Cancer
Explore This Issue
November 2019

Another important point is that a significant number of patients with HPV+ oropharynx cancer have extensive smoking histories. “We don’t know as much about this population as we should,” Dr. Sikora said. “We know that they have worse outcomes than HPV+ oropharynx cancer patients without a history of tobacco use, but this is not reflected in our current staging system, which automatically downstages patients with a HPV+ tumor. Therefore, these patients are at serious risk for undertreatment.”

Overall, rather than focusing single-mindedly on de-escalation of HPV-associated oropharynx cancer, Dr. Sikora believes tools need to be developed that will allow clinicians to risk assess individual patients and deliver the treatment they need. “In many cases, this will involve de-escalating treatment relative to what has been the standard, but for others we will need to intensify treatment,” he said. “We need to invest in the necessary research to develop the algorithms and predictive markers that will allow us to evaluate a patient’s tumor, and determine with confidence the treatment with the greatest chance of cure and lowest risk of long-term toxicity.”

Dr. Ramey added that radiotherapy is an excellent treatment option for many patients and that patients should have the chance to discuss this highly successful treatment option with a radiation oncologist. “However, there is no one right way to treat every patient with oropharyngeal cancer, since treating physicians need to take into account a patient’s preferences, the specifics of each patient’s cancer, and a patient’s other medical co-morbidities,” he said. “Therefore, clinicians must be a part of a team helping patients make an informed decision.”

Outlook

Radiotherapy is going to be part of the treatment strategy for patients with HPV+ oropharynx cancer for a long time, Dr. Sikora said. “Right now, standard chemo-radiotherapy regimens are very effective, but also very difficult for patients,” he said. “The combination of radiotherapy and immunotherapy is being actively tested in clinical trials, and is likely to eventually enter the standard-of-care in one form or another. Even patients treated with surgery often require adjuvant radiotherapy or chemo-radiotherapy to maximize their chance of a long-term cure. So radiotherapy is not going anywhere anytime soon.”

Nevertheless, the way radiation is delivered has evolved, and will continue to do so. “The development of intensity-modulated radiotherapy (IMRT), which focuses radiation on the tumor and decreases the dose received by normal tissues, was an important step toward decreasing toxicity,” Dr. Sikora said. “We are now actively discussing the de-escalation of radiation for patients with HPV+ oropharynx cancer with favorable characteristics. There is also the future possibility, if supported by clinical trials, of reducing or replacing chemotherapy with immunotherapy for some patients, since overall it has a less punishing toxicity profile.”

Dr. Page also believes that radiotherapy will remain in use for the foreseeable future, despite its drawbacks. “It’s still the main curative therapy, particularly for patients with locally advanced oropharyngeal squamous cell carcinomas,” she said. “While current clinical trial efforts include examining de-escalation therapy to try to reduce either chemotherapy or radiotherapy or both, more work needs to be done to further elucidate the extent of therapy needed to adequately treat this disease.”   

Pages: 1 2 3 4 | Single Page

Filed Under: Features, Head and Neck, Practice Focus Tagged With: head and neck cancer, HPV, HPV-positive oropharyngeal cancer, radiation therapyIssue: November 2019

You Might Also Like:

  • Study: Surgery, Radiation Therapy Equally Effective in Treating OPSCC
  • Primary Radiation vs. Primary Surgical Therapy for Cervical Esophageal Cancer
  • Fanconi Anemia Patients with HNSCC Tolerate Surgery Better than Radiation, Chemotherapy
  • HPV-Positive Oropharnygeal Cancer Has Better Prognosis than Tobacco-Induced Cancer

The Triological SocietyENTtoday is a publication of The Triological Society.

Polls

Would you choose a concierge physician as your PCP?

View Results

Loading ... Loading ...
  • Polls Archive

Top Articles for Residents

  • Applications Open for Resident Members of ENTtoday Edit Board
  • How To Provide Helpful Feedback To Residents
  • Call for Resident Bowl Questions
  • New Standardized Otolaryngology Curriculum Launching July 1 Should Be Valuable Resource For Physicians Around The World
  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Keeping Watch for Skin Cancers on the Head and Neck

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • 22 Symptoms Common to Patients with Superior Canal Dehiscence Syndrome

    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Complications for When Physicians Change a Maiden Name

    • Excitement Around Gene Therapy for Hearing Restoration
    • “Small” Acts of Kindness
    • How To: Endoscopic Total Maxillectomy Without Facial Skin Incision
    • Science Communities Must Speak Out When Policies Threaten Health and Safety
    • Observation Most Cost-Effective in Addressing AECRS in Absence of Bacterial Infection

Follow Us

  • Contact Us
  • About Us
  • Advertise
  • The Triological Society
  • The Laryngoscope
  • Laryngoscope Investigative Otolaryngology
  • Privacy Policy
  • Terms of Use
  • Cookies

Wiley

Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1559-4939